CKD with particular reference to IgA nephropathy
Conditions
Interventions
Group 1: A blood sample of patients with IgA nephropathy will be proceeded once to examine the phase I and II gene
Group 2: Control group with frequencies of enzyme variations in the general populatio
Sponsors
Nephrologische Praxis
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Histologic proven IgA nephropathy in Caucasians of either sex For the controls: chronic kidney disease patients without glomerulonephritis in Caucasians of either sex Further controls: published SNP- frequencies of phase I and II gene (rate of polymorphisms in the general population)
Exclusion criteria
Exclusion criteria: none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalences of genetic variants in enzymes of phase I and II will be assessed in patients with histologic proven IgA nephropathy. Genetic variants will be analysed by means of DNA from EDTA blood samples and set in comparison to the prevalence in chronic kidney disease patients without glomerulonephritis as well as to the published SNP (single nucleotide polymorphism) frequencies of data bases. | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression of the disease based on GFR in relation to the number of genetic variants | — |
Countries
Germany
Contacts
Public ContactHans-Ulrich Mayr
MVZ Diaverum Neubrandenburg, Nephrologische Abteilung
Outcome results
None listed